GeneDx Holdings Reports Q1 Earnings Shortfall and Lowers Revenue Guidance
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 06 2026
0mins
Source: stocktwits
GeneDx Holdings Corp. shares fell 45.53% in pre-market trading as the stock crossed below its 5-day SMA, reflecting investor concerns following disappointing earnings results.
The company reported Q1 2026 earnings that missed expectations, with total revenue of $102.3 million, below the anticipated $110 million. Additionally, GeneDx lowered its 2026 revenue guidance to a range of $475 million to $490 million, significantly down from previous estimates, indicating challenges in market dynamics that could undermine investor confidence. Despite a 34% year-over-year increase in exome and genome testing volume, the overall outlook remains bleak due to competitive pressures and operational inefficiencies.
This significant drop in stock price highlights the market's reaction to the company's revised guidance and earnings miss, prompting investors to reassess their positions amid ongoing uncertainties in the healthcare sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy WGS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on WGS
Wall Street analysts forecast WGS stock price to rise
8 Analyst Rating
7 Buy
1 Hold
0 Sell
Strong Buy
Current: 56.420
Low
155.00
Averages
171.43
High
200.00
Current: 56.420
Low
155.00
Averages
171.43
High
200.00
About WGS
GeneDx Holdings Corp. is a genomics company. The Company operates, through its subsidiary, GeneDx, LLC, which is focused on exome and genome tests that translate complex genomic data into clinical answers that unlock personalized health plans, accelerate drug discovery, and improve health system efficiencies. It operates through the GeneDx segment, which primarily provides pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing and, to a lesser extent, data and information services. Genomic sequencing tests include whole genome sequencing, whole exome sequencing, prenatal genetic testing, targeted testing, pediatric neurology, general pediatrics, geneticists and genetic counsellors, and others. It offers a menu of targeted variant testing options to meet the needs of families and healthcare providers. Its subsidiary, Fabric Genomics, Inc., specializes in artificial intelligence-powered genomic interpretation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Reminder for GeneDx Shareholder Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased GeneDx common stock between April 16, 2025, and May 4, 2026, to apply as lead plaintiffs by August 3, 2026, to participate in the class action without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that GeneDx made false statements regarding the acquisition of Fabric, misleading investors into believing it would enhance financial performance, while in reality, the acquisition negatively impacted GeneDx's overall business operations.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and recovered over $438 million for investors in 2019 alone, being ranked first by ISS for the number of securities class action settlements in 2017, showcasing its expertise in this field.
- Investor Guidance: The firm advises investors to select qualified counsel with a proven track record to avoid partnering with inexperienced intermediaries, ensuring their rights are effectively protected in the class action process.
See More
Securities Fraud Class Action Filed Against GeneDx Holdings Corp.
- Lawsuit Background: Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action against GeneDx Holdings Corp. (NASDAQ:WGS) on behalf of investors who purchased WGS stock between April 16, 2025, and May 4, 2026, highlighting significant investor concerns regarding the company's financial transparency.
- Acquisition Deal Details: GeneDx announced an agreement to acquire Fabric Genomics for up to $51 million, including $33 million in cash, aimed at expanding its market through AI-driven genomic interpretation; however, the viability of this acquisition has been questioned, leading to a decline in investor confidence.
- Deteriorating Financial Performance: In its first quarter of 2026, GeneDx reported a drop in adjusted gross margin, lowered earnings projections, and disclosed a $31.3 million impairment loss related to Fabric, which directly impacted its stock price, causing a decline of over 49% following the announcement.
- Investor Action Recommendations: Affected investors are encouraged to apply for lead plaintiff status in the class action by August 3, 2026, representing the interests of all impacted investors, underscoring the importance of legal avenues in protecting investor rights.
See More
GeneDx Faces Securities Class Action After Stock Plunge
- Stock Price Crash: GeneDx's stock plummeted by $33.42 (-49%) on May 5, 2026, following a disastrous Q1 earnings report, severely undermining investor confidence and exposing the company to a securities class action lawsuit.
- Deteriorating Financial Performance: The company reported a tenfold increase in net loss for Q1 2026 compared to the previous year, with the Fabric Genomics unit missing revenue expectations by $2.5 million, leading to a $31.2 million impairment charge, nearly 94% of its acquisition cost.
- Revenue Guidance Cut: GeneDx slashed its 2026 revenue guidance by 12%, stating that genome and exome revenue growth would be at least 20%, significantly lower than prior forecasts, indicating a major adverse shift in product mix.
- Legal Investigation Initiated: Hagens Berman is investigating whether GeneDx intentionally or recklessly misled investors regarding the true value of Fabric Genomics and its impact on growth expectations, potentially resulting in substantial investor losses.
See More
GeneDx Faces Class Action Lawsuit Reminder for Investors
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against GeneDx for violations of securities laws, urging those who purchased securities between April 16, 2025, and May 4, 2026, to contact the firm by August 3, 2026, to participate.
- Declining Financial Performance: GeneDx reported a drop in adjusted gross margin and lowered earnings projections in its Q1 2026 financial results released on May 4, 2026, alongside a $31.3 million impairment related to Fabric Genomics, indicating a deterioration in the company's financial health.
- False Statement Allegations: The complaint alleges that GeneDx made false and misleading public statements throughout the class period, resulting in investor losses when the truth emerged, highlighting significant deficiencies in the company's disclosure practices.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations for affected investors, encouraging them to understand their rights, which underscores the firm's focus on securities class action lawsuits aimed at helping investors recover losses.
See More
Faruqi & Faruqi Encourages GeneDx Investors to Reach Out
- Legal Investigation: Faruq & Faruqi LLP is investigating potential claims against GeneDx Holdings Corp., particularly for investors who purchased or acquired securities between April 16, 2025, and May 4, 2026, indicating concerns about the company's financial health.
- Investor Rights Reminder: The firm reminds investors that August 3, 2026, is the deadline to seek the role of lead plaintiff in a federal securities class action, highlighting the time sensitivity and importance of investor participation in legal proceedings.
- Direct Contact Channels: Securities Litigation Partner Josh Wilson encourages affected investors to contact him directly at 877-247-4292 or 212-983-9330 (Ext. 1310), providing a clear avenue for legal support and guidance.
- Market Reaction Expectations: Such legal actions could negatively impact GeneDx's stock price, prompting investors to monitor developments closely to assess potential financial losses and legal risks.
See More
GeneDx Holdings Faces Securities Fraud Class Action Lawsuit
- Lawsuit Background: GeneDx Holdings Corp. (NASDAQ: WGS) is facing a securities fraud class action lawsuit for alleged material misstatements regarding its acquisition of Fabric Genomics during the period from April 16, 2025, to May 4, 2026, which has significantly impacted investor confidence.
- Acquisition Details: The company announced an agreement to acquire Fabric Genomics for up to $51 million, with $33 million in cash upfront, aiming to expand its market through AI-driven genomic interpretation; however, it later faced significant viability issues with Fabric, leading to investor losses.
- Financial Impact: On May 4, 2026, GeneDx reported a drop in adjusted gross margin and lowered earnings projections, disclosing a $31.3 million impairment loss related to Fabric, causing its stock price to plummet by over 49% following the announcement.
- Investor Action: Affected investors are encouraged to file for lead plaintiff status by August 3, 2026, with KTMC offering free case evaluations and operating on a contingency fee basis, urging investors to take proactive steps to protect their legal rights.
See More
Reminder for GeneDx Shareholder Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased GeneDx common stock between April 16, 2025, and May 4, 2026, to apply as lead plaintiffs by August 3, 2026, to participate in the class action without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that GeneDx made false statements regarding the acquisition of Fabric, misleading investors into believing it would enhance financial performance, while in reality, the acquisition negatively impacted GeneDx's overall business operations.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and recovered over $438 million for investors in 2019 alone, being ranked first by ISS for the number of securities class action settlements in 2017, showcasing its expertise in this field.
- Investor Guidance: The firm advises investors to select qualified counsel with a proven track record to avoid partnering with inexperienced intermediaries, ensuring their rights are effectively protected in the class action process.
See More
Securities Fraud Class Action Filed Against GeneDx Holdings Corp.
- Lawsuit Background: Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action against GeneDx Holdings Corp. (NASDAQ:WGS) on behalf of investors who purchased WGS stock between April 16, 2025, and May 4, 2026, highlighting significant investor concerns regarding the company's financial transparency.
- Acquisition Deal Details: GeneDx announced an agreement to acquire Fabric Genomics for up to $51 million, including $33 million in cash, aimed at expanding its market through AI-driven genomic interpretation; however, the viability of this acquisition has been questioned, leading to a decline in investor confidence.
- Deteriorating Financial Performance: In its first quarter of 2026, GeneDx reported a drop in adjusted gross margin, lowered earnings projections, and disclosed a $31.3 million impairment loss related to Fabric, which directly impacted its stock price, causing a decline of over 49% following the announcement.
- Investor Action Recommendations: Affected investors are encouraged to apply for lead plaintiff status in the class action by August 3, 2026, representing the interests of all impacted investors, underscoring the importance of legal avenues in protecting investor rights.
See More
GeneDx Faces Securities Class Action After Stock Plunge
- Stock Price Crash: GeneDx's stock plummeted by $33.42 (-49%) on May 5, 2026, following a disastrous Q1 earnings report, severely undermining investor confidence and exposing the company to a securities class action lawsuit.
- Deteriorating Financial Performance: The company reported a tenfold increase in net loss for Q1 2026 compared to the previous year, with the Fabric Genomics unit missing revenue expectations by $2.5 million, leading to a $31.2 million impairment charge, nearly 94% of its acquisition cost.
- Revenue Guidance Cut: GeneDx slashed its 2026 revenue guidance by 12%, stating that genome and exome revenue growth would be at least 20%, significantly lower than prior forecasts, indicating a major adverse shift in product mix.
- Legal Investigation Initiated: Hagens Berman is investigating whether GeneDx intentionally or recklessly misled investors regarding the true value of Fabric Genomics and its impact on growth expectations, potentially resulting in substantial investor losses.
See More
GeneDx Faces Class Action Lawsuit Reminder for Investors
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against GeneDx for violations of securities laws, urging those who purchased securities between April 16, 2025, and May 4, 2026, to contact the firm by August 3, 2026, to participate.
- Declining Financial Performance: GeneDx reported a drop in adjusted gross margin and lowered earnings projections in its Q1 2026 financial results released on May 4, 2026, alongside a $31.3 million impairment related to Fabric Genomics, indicating a deterioration in the company's financial health.
- False Statement Allegations: The complaint alleges that GeneDx made false and misleading public statements throughout the class period, resulting in investor losses when the truth emerged, highlighting significant deficiencies in the company's disclosure practices.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations for affected investors, encouraging them to understand their rights, which underscores the firm's focus on securities class action lawsuits aimed at helping investors recover losses.
See More
Faruqi & Faruqi Encourages GeneDx Investors to Reach Out
- Legal Investigation: Faruq & Faruqi LLP is investigating potential claims against GeneDx Holdings Corp., particularly for investors who purchased or acquired securities between April 16, 2025, and May 4, 2026, indicating concerns about the company's financial health.
- Investor Rights Reminder: The firm reminds investors that August 3, 2026, is the deadline to seek the role of lead plaintiff in a federal securities class action, highlighting the time sensitivity and importance of investor participation in legal proceedings.
- Direct Contact Channels: Securities Litigation Partner Josh Wilson encourages affected investors to contact him directly at 877-247-4292 or 212-983-9330 (Ext. 1310), providing a clear avenue for legal support and guidance.
- Market Reaction Expectations: Such legal actions could negatively impact GeneDx's stock price, prompting investors to monitor developments closely to assess potential financial losses and legal risks.
See More
GeneDx Holdings Faces Securities Fraud Class Action Lawsuit
- Lawsuit Background: GeneDx Holdings Corp. (NASDAQ: WGS) is facing a securities fraud class action lawsuit for alleged material misstatements regarding its acquisition of Fabric Genomics during the period from April 16, 2025, to May 4, 2026, which has significantly impacted investor confidence.
- Acquisition Details: The company announced an agreement to acquire Fabric Genomics for up to $51 million, with $33 million in cash upfront, aiming to expand its market through AI-driven genomic interpretation; however, it later faced significant viability issues with Fabric, leading to investor losses.
- Financial Impact: On May 4, 2026, GeneDx reported a drop in adjusted gross margin and lowered earnings projections, disclosing a $31.3 million impairment loss related to Fabric, causing its stock price to plummet by over 49% following the announcement.
- Investor Action: Affected investors are encouraged to file for lead plaintiff status by August 3, 2026, with KTMC offering free case evaluations and operating on a contingency fee basis, urging investors to take proactive steps to protect their legal rights.
See More
